Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$7.25 USD
-0.16 (-2.16%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.24 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LFCR 7.25 -0.16(-2.16%)
Will LFCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates
Other News for LFCR
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August ...
Laughing Water Capital Q2 2025 Letter
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LFCR Stock News
Stock Picks From Seeking Alpha's June 2025 New Analysts
Lifecore Biomedical: Inflecting Financials Over Next 3 Years